Evaluation of the effects of add-on treatment with Atorvastatin on cognitive deficits in schizophrenic patients
- Conditions
- schizophrenia.Schizophrenia
- Registration Number
- IRCT20190621043962N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 64
Diagnosis of schizophrenia based on DSM-5
patients between 18 and 64 years
Informed consent by the patients and a member of his/her family
Minimum eighth grade education
No psychiatric comorbidity
No medical comorbidity
No substance use, except for cigarettes
No history of hypersensitivity reaction or intolerable side effects with Atorvastatin
No concomitant drugs that they interact with Atorvastatin (Anti-inflammatory drugs such as Aspirin and Ibuprofen, Thiazide diuretics, weight-loss drugs, anti-fungal drugs, Macrolids, Colchicin, Protease inhibitors)
No pregnancy or breastfeeding (for women)
No history of major head trauma
No participation in other study in the time of this study
No major cognitive deficits comorbidity
Failure to the patient or his/her family to continue the study
Occurrence of any serious side effects during the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive state. Timepoint: At the outset of the study (before intervention), at 21 days 42 days after starting Atorvastatin. Method of measurement: PANSS test, Stroop test, Digit span test, Verbal fluency test, Wechsler test, Wisconsin Card Sorting test, and Trial making test.
- Secondary Outcome Measures
Name Time Method Positive and negative symptoms score. Timepoint: At the outset of the study (before intervention), and at 3 and 6 weeks after starting Atorvastatin. Method of measurement: Positive and Negative Symptoms Scale test.